2.3. Study Procedures
Patients were randomly assigned 1:1:1 to receive either probenecid 500 mg or 1000 mg b.i.d., or matching placebo b.i.d. for five days. Patients were blinded to study drug assignment while study personnel were unblinded. Patients were seen in the clinic on days 0 (screening visit), 1, 3, 5, 10, 15, and 28 (end-of-study visit). Safety and laboratory tests (hematology and biochemistry) were performed on days 1, 5, and 28, with a complete physical examination on days 0 and 28. Vital signs assessments, i.e., body temperature, blood pressure, oxygen saturation, respiratory rate, and heart rate, were established according to the WHO clinical progression scale [